Bioventus Reports Third Quarter Financial Results
Bioventus Inc. - Class A (BVS)
Company Research
Source: GlobeNewswire
Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per diluted shareNon-GAAP earnings* of $0.15 per diluted share increased 200%Cash from operations of $30.1 million increased 192%Company reaffirms revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 27, 2025. "Momentum continued to build across our portfolio as our team delivered an exceptional quarter reflecting above-market organic* revenue growth, increased profitability, and significant cash flow acceleration,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “Looking ahead, we remain commit
Show less
Read more
Impact Snapshot
Event Time:
BVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BVS alerts
High impacting Bioventus Inc. - Class A news events
Weekly update
A roundup of the hottest topics
BVS
News
- Bioventus: A New Start [Seeking Alpha]Seeking Alpha
- Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Bioventus to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Bioventus (NASDAQ:BVS) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Bioventus reiterates 2025 guidance with 6%–8% organic growth target as PNS and PRP launches gain traction [Seeking Alpha]Seeking Alpha
BVS
Earnings
- 8/6/25 - Miss
BVS
Sec Filings
- 12/4/25 - Form 144
- 11/25/25 - Form 3
- 11/17/25 - Form 8-K
- BVS's page on the SEC website